By Devika Patel
Knoxville, Tenn., June 16 - Aeterna Zentaris Inc. gave further details about a $12.09 million registered direct offering of units in a prospectus supplement filed Wednesday with the Securities and Exchange Commission. The deal priced on June 15.
The company will sell 8,805,964 units of one common share and a half-share warrant at $1.3725 apiece. The whole warrants are exercisable at $1.3725 for five years.
Rodman & Renshaw, LLC is the agent.
Settlement is expected on June 18.
Proceeds will be used to fund the company's AEZS-108, AEZS-112 and AEZS-130 programs and for other general corporate and working capital purposes.
Aeterna Zentaris is a biopharmaceutical company focused on endocrine therapy and oncology based in Quebec City, Quebec.
| Issuer: | Aeterna Zentaris Inc.
|
| Issue: | Units of one common share and a half-share warrant
|
| Amount: | $12,086,186
|
| Shares: | 8,805,964
|
| Price: | $1.3725
|
| Warrants: | One half-share warrant per unit
|
| Warrant expiration: | Five years
|
| Warrant strike price: | $1.3725
|
| Agent: | Rodman & Renshaw, LLC
|
| Pricing date: | June 15
|
| Settlement date: | June 18
|
| Stock symbol: | Nasdaq: AEZS
|
| Stock price: | $1.31 at close June 15
|
| Market capitalization: | $87.6 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
